Hematocrit on TRT: Why It Rises, When to Donate Blood, and What the Research Says

What hematocrit measures and why it matters on TRT

Hematocrit on TRT is the single most frequently flagged lab value in men on testosterone therapy. Hematocrit (Hct) is the percentage of your blood volume occupied by red blood cells. A value of 48% means that 48% of your whole blood is red cells and 52% is plasma and other components. It rises when red blood cell mass increases or when plasma volume contracts (dehydration).

On TRT, the rise is almost always driven by an actual increase in red cell mass — a phenomenon called secondary erythrocytosis. It is not the same as polycythemia vera, a bone marrow disease driven by a JAK2 mutation, though both conditions share elevated hematocrit as a feature. The distinction matters clinically: treatment, prognosis, and workup are different.

For the broader context on monitoring, start with our TRT blood work pillar guide. For the companion post on the other commonly-misread TRT lab marker, see estradiol on TRT.

Why hematocrit rises on testosterone therapy

Testosterone is a potent stimulator of erythropoiesis, the process by which the body produces red blood cells. Researchers have characterized at least three mechanisms that are likely to act together:

1. Erythropoietin (EPO) signaling. Testosterone increases EPO production by the kidneys and shifts the EPO-to-hemoglobin set point upward, so the body tolerates a higher red cell mass before downregulating EPO. This is described in work by Bachman and colleagues (Journal of Gerontology, 2014).
2. Hepcidin suppression. Hepcidin is a liver-produced hormone that regulates iron availability. Testosterone suppresses hepcidin, which increases iron available to erythroid precursors in bone marrow. More available iron means more hemoglobin and more red blood cells.
3. Direct bone marrow effects. Androgen receptors are expressed on erythroid progenitor cells. Testosterone appears to act directly on these cells to promote differentiation and proliferation.

The practical consequence is that red cell mass on TRT is a dose-dependent and kinetics-dependent phenomenon. Higher weekly doses produce a larger rise. Larger single doses with wider peak-to-trough swings produce more erythropoietic stimulus than flatter delivery profiles at the same weekly total.

How much does hematocrit actually rise on TRT?

A meta-analysis by Ohlander et al. in Sexual Medicine Reviews (2018) summarized dozens of TRT trials and reported that the incidence of erythrocytosis — variably defined in the literature as hematocrit above 50-54% — was meaningfully higher in men on intramuscular testosterone than on transdermal therapy, with pooled incidences ranging from roughly 11% to 40% depending on the study and threshold used. Pellets fell between the two.

The take-home signal from that body of research is consistent:

• Expect some rise in hematocrit on any effective TRT protocol.
• The rise usually plateaus within 3 to 6 months of a stable dose.
• The higher the peak testosterone, the higher the peak erythropoietic drive.
• Baseline upper-normal hematocrit is a risk factor for hitting the clinical threshold after starting TRT.

Visualizing the dose-and-frequency effect

The conceptual chart below shows the typical pattern: same weekly testosterone dose, very different hematocrit trajectories depending on injection frequency and delivery method. The numbers are illustrative and drawn from the general pattern in published pharmacokinetic literature, not from a single trial.

Delivery method: injections vs gel vs pellets

The peer-reviewed literature is relatively consistent on the rank order of erythropoietic impact, holding weekly dose roughly constant:

Intramuscular injections (weekly or every two weeks)

The largest hematocrit rise of the common delivery methods. Peak testosterone after injection is typically supraphysiological for 24-72 hours, which drives the strongest erythropoietic stimulus. Every-two-week cypionate/enanthate protocols — still common in traditional urology practice — produce the highest peaks and the largest hematocrit effects. Compare the delivery methods in detail in our TRT gel vs injections guide.

Subcutaneous injections (twice-weekly or every-other-day)

Smaller, more frequent subcutaneous doses produce lower peaks. Studies and clinical experience suggest the hematocrit rise is meaningfully smaller than with once-weekly IM dosing at the same total weekly amount. This is the primary reason many prescribers move to SC twice-weekly or every-other-day when a patient is bumping against the hematocrit threshold.

Transdermal gel and patches

Daily transdermal delivery produces the flattest pharmacokinetic curve of the common TRT methods. Hematocrit rise tends to be the smallest, making gel a reasonable option for men who cannot tolerate the erythropoietic effects of injections. Gel has its own drawbacks — transfer risk to partners and children, absorption variability, and cost — covered in our gel vs injections comparison.

Pellets

Testosterone pellets deliver a large bolus that decays over 3-6 months. Peak testosterone after implantation can be substantial, and some men experience significant hematocrit increases. Once pellets are in, dose adjustments are not possible until the next implantation cycle, which is a relevant consideration for men who trend toward high hematocrit. See pellets vs injections for a deeper comparison.

The 54% threshold and what physicians watch for

The most frequently cited clinical threshold for intervention is hematocrit > 54%. This number comes directly from the Endocrine Society's 2018 clinical practice guideline (Bhasin et al., Journal of Clinical Endocrinology & Metabolism), which recommends evaluating patients whose hematocrit rises above 54% on testosterone therapy. The 2024 AUA guideline update is consistent with this threshold.

Why 54%? It is a pragmatic cutoff derived from the upper end of observed normal distributions and from older evidence that blood viscosity and thrombotic risk rise more steeply above that point. It is not a bright line where risk changes dramatically at 53.9% versus 54.1%. It is the point at which guidelines say clinicians should re-examine the protocol.

What a prescriber typically considers at or above 54%

• Whether the reading is confirmed on a repeat draw (a single elevated value could be dehydration or lab variability)
• Whether trough testosterone is supraphysiological, suggesting the dose is simply too high
• Whether injection frequency can be split to flatten peaks
• Whether delivery method could be changed (IM to SC, or injection to gel)
• Whether comorbidities (sleep apnea, smoking, COPD, high altitude residence, polycythemia vera) are contributing
• Whether therapeutic phlebotomy or blood donation is appropriate
• Whether TRT should be paused pending evaluation

Comparing published thresholds side-by-side

The table below is a plain-text summary of how major sources frame hematocrit thresholds on TRT. Specific dose and schedule decisions belong to your prescriber.

Does high hematocrit on TRT raise cardiovascular risk?

This is the central safety question and the one where honest interpretation of the evidence matters most.

The biological case for concern

Elevated hematocrit increases blood viscosity. Higher viscosity, in principle, increases the workload on the heart and can contribute to thrombosis. Erythrocytosis in primary polycythemia vera is a known independent risk factor for venous thromboembolism and arterial events. This is the pathophysiologic rationale for the 54% threshold.

What TRAVERSE showed

The TRAVERSE trial (Lincoff et al., New England Journal of Medicine, 2023) was the largest randomized cardiovascular safety trial of testosterone therapy. It enrolled 5,246 men aged 45-80 with hypogonadism and pre-existing cardiovascular risk, randomizing them to transdermal testosterone or placebo. Over a mean follow-up of approximately 33 months:

• The primary composite cardiovascular endpoint (MACE — cardiovascular death, nonfatal MI, nonfatal stroke) was not significantly different between testosterone and placebo groups. Testosterone met the pre-specified non-inferiority criterion.
• Pulmonary embolism was numerically more common in the testosterone group (0.9% vs 0.5%).
• Atrial fibrillation was also numerically higher in the testosterone group (3.5% vs 2.4%).
• Acute kidney injury and nephrolithiasis were also numerically higher with testosterone.

TRAVERSE used transdermal gel, not injections — the delivery method associated with the smallest hematocrit rise. Whether the cardiovascular signals would have been more pronounced with higher-peak injection protocols is not directly answered by the trial.

What the TRAVERSE data do not say

• They do not say that high hematocrit on TRT is harmless.
• They do not say that 54% is the wrong threshold.
• They do not generalize directly to intramuscular injection protocols at supraphysiological doses.
• They do not cover men under 45 or men without pre-existing cardiovascular risk factors.

The honest read is that TRAVERSE reassures on broad MACE outcomes in the population studied but identifies specific signals (PE, AFib) that keep hematocrit management clinically important. This is why guidelines retain the 54% threshold even post-TRAVERSE. Our side effects pillar guide walks through cardiovascular monitoring more broadly.

Therapeutic phlebotomy vs blood donation

When hematocrit needs to be lowered mechanically, there are two pathways: therapeutic phlebotomy (ordered by a physician) and standard blood donation (community blood bank). They look similar procedurally — a needle, a bag, and about 500 mL of blood — but the regulatory, logistical, and cost structures are different.

Therapeutic phlebotomy

• Requires a physician order specifying the clinical indication and target
• Performed at hospitals, infusion centers, or blood centers with a prescription
• Blood is generally not used for transfusion because the donor has a medical condition requiring phlebotomy
• Often billable to insurance with an appropriate ICD-10 code (e.g., secondary polycythemia)
• Available regardless of standard donation eligibility — this is the pathway if Red Cross turns you away

Standard blood donation

• Voluntary, no physician order needed
• Performed at blood centers, blood drives, and mobile collection events
• Blood is intended for transfusion to other patients, so donor screening is rigorous
• Free to the donor but governed by eligibility rules set by the collection agency
• Not always available to men on TRT — eligibility depends on the donation center's policy

Which one is right for you?

If you are eligible for community blood donation and your prescriber approves it as an adequate hematocrit-management strategy, donation is simpler, free, and benefits others. If you are ineligible — or if your prescriber wants a documented clinical procedure with defined targets — therapeutic phlebotomy is the right pathway. Either way, frequency is set by your prescriber based on your hematocrit trend, not a fixed schedule.

Red Cross donation eligibility for TRT patients

The American Red Cross publishes eligibility criteria for blood donation, and these can change. Historically, several factors relevant to TRT patients have affected eligibility:

• Hemoglobin & hematocrit cutoffs: The Red Cross requires hemoglobin within a specific range at the time of donation. Donors with hematocrit above the upper acceptable limit have historically been deferred.
• Medication review: Injectable testosterone prescriptions are reviewed during screening; some centers historically deferred donors whose elevated counts were drug-induced.
• Donation frequency limits: Whole blood donation is capped at roughly once every 56 days in healthy donors — not frequent enough to serve as primary hematocrit management for many TRT patients.

Eligibility policies vary across blood centers (Red Cross, Vitalant, hospital-based donor programs, community blood banks). Some centers accept TRT patients readily; others do not. Call the specific center before a trip.

What prescribers consider before donation

Blood donation or therapeutic phlebotomy is not automatically the first move at an elevated hematocrit reading. Prescribers typically look at protocol-level levers first, because those fix the underlying driver rather than repeatedly removing the downstream product.

Protocol-level adjustments a prescriber may evaluate

1. Confirm the reading. A single elevated hematocrit warrants a repeat draw, ideally at trough, hydrated, and using the same lab.
2. Review dose. If trough total testosterone is supraphysiological, dose reduction addresses multiple side effects at once — hematocrit, E2, water retention — and is often the cleanest lever. For a detailed look at what "supraphysiological" means in practice, see our 200mg testosterone results article.
3. Increase injection frequency. Moving from once-weekly to twice-weekly (or every-other-day) injections reduces peak testosterone and, in turn, peak erythropoietic drive.
4. Change delivery method. In select cases, moving from IM injection to transdermal gel is considered for men whose hematocrit cannot otherwise be controlled.
5. Address contributors. Untreated sleep apnea is a major non-TRT cause of elevated hematocrit and a common missed diagnosis. Smoking, chronic hypoxia, and certain medications also contribute. See the side effects pillar for the overlap with sleep apnea.
6. Hydration. Chronic mild dehydration can add a point or two to hematocrit readings. Not a substitute for protocol management, but a correctable confounder.

A brief scenario

A 48-year-old man six months into once-weekly 200 mg testosterone cypionate IM has trough total T of 1,250 ng/dL and hematocrit of 55%. His prescriber repeats the draw (confirmed), reduces his dose to 160 mg/week split into 80 mg twice weekly subcutaneously, and orders a single therapeutic phlebotomy. Three months later, trough T is 950 ng/dL, hematocrit is 49%, and he is feeling better overall. The protocol change, not the phlebotomy, is doing most of the work. This pattern is representative.

How often to check hematocrit on TRT

Monitoring cadences vary by prescriber and patient factors, but a typical framework looks roughly like this:

• Baseline: CBC before starting TRT, to document the starting point and rule out pre-existing erythrocytosis
• 3 months: First post-start CBC alongside testosterone and E2; often the earliest point where a significant rise is visible
• 6 months: Follow-up CBC if the 3-month value was near the upper limit, or if dose was adjusted
• Annually: Once stable, at least once yearly with the full TRT monitoring panel
• More often: Men who are on higher doses, men who crossed 52-53% on a prior draw, men with sleep apnea, and men post-protocol-change may need draws every 3-6 months

Your prescriber sets your individualized schedule. For the full TRT lab panel beyond hematocrit, see our blood work pillar and the companion estradiol on TRT article.

When hematocrit becomes urgent

Most hematocrit changes on TRT are gradual and non-urgent. A handful of scenarios deserve prompter attention.

Contact your prescriber promptly

1. A confirmed hematocrit above 54% on a repeat draw
2. A sudden jump of more than a few points between routine draws at the same timing and hydration
3. New headaches, dizziness, flushing, or visual changes coinciding with a rising trend
4. New unexplained leg swelling, calf pain, or shortness of breath (possible DVT/PE — these are emergency symptoms requiring urgent evaluation, not a next-day call)
5. Chest pain, one-sided weakness, slurred speech, or sudden severe headache — call emergency services immediately

Things that look scary but usually are not

• A single hematocrit reading slightly above a lab's reference range in a well-hydrated, asymptomatic man on stable TRT
• A 2-3 point rise in the first 3-6 months, plateauing thereafter
• A peak-draw hematocrit that appears elevated compared to prior trough draws
• A friend's hematocrit reading being different from yours — individual responses vary widely

The bottom line

Hematocrit is a predictable, dose-dependent feature of testosterone therapy, not a surprise side effect. The 54% threshold exists because hyperviscosity is biologically plausible as a risk factor, even as TRAVERSE-era evidence softens some of the historical cardiovascular worry about TRT more broadly. Management is layered: confirm the value, address the protocol first, use therapeutic phlebotomy or donation when the protocol adjustments are not enough, and keep a regular monitoring cadence.

If you want broader context on how this fits with other TRT lab markers, start with the blood work pillar guide, then work through estradiol on TRT and the side effects pillar. If you are weighing alternative therapies that avoid supraphysiological testosterone entirely, compare enclomiphene vs TRT and clomid vs TRT. For a look at how side effects tend to evolve over the first year, see the full TRT before and after timeline.